Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation in Metastatic Colorectal Cancer as a Novel Adoptive Cell Therapy Approach. The European Group for Blood and Marrow Transplantation Experience

Aglietta, Massimo; Barkholt, Lisbeth; Schianca, Fabrizio Carnevale; Caravelli, Daniela; Omazic, Brigitta; Minotto, Coludia; Leone, Francesco; Hentschke, P; Bertoldero, Giovanni; Capaldi, Antonio; Ciccone, Giovannino; Niederwieser, Dietger; Ringdén, Olle; Demirer, T.

doi:10.1016/j.bbmt.2008.11.036

Cited by 26 publications

(12 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Even metastatic CRC need intense GVT to eradicate spreading tumor cells. Allogeneic SCT is likely to have trigged the generation of anti-neoplastic T cells [238-240]. …”

Section: Cancermentioning

confidence: 99%

Stem cells in clinical practice: applications and warnings

Lodi

Iannitti

Palmieri

2011

J Exp Clin Cancer Res

168

113

View full text Add to dashboard Cite

Stem cells are a relevant source of information about cellular differentiation, molecular processes and tissue homeostasis, but also one of the most putative biological tools to treat degenerative diseases. This review focuses on human stem cells clinical and experimental applications. Our aim is to take a correct view of the available stem cell subtypes and their rational use in the medical area, with a specific focus on their therapeutic benefits and side effects. We have reviewed the main clinical trials dividing them basing on their clinical applications, and taking into account the ethical issue associated with the stem cell therapy.MethodsWe have searched Pubmed/Medline for clinical trials, involving the use of human stem cells, using the key words "stem cells" combined with the key words "transplantation", "pathology", "guidelines", "properties" and "risks". All the relevant clinical trials have been included. The results have been divided into different categories, basing on the way stem cells have been employed in different pathological conditions.

show abstract

“…Even metastatic CRC need intense GVT to eradicate spreading tumor cells. Allogeneic SCT is likely to have trigged the generation of anti-neoplastic T cells [238-240]. …”

Section: Cancermentioning

confidence: 99%

Stem cells in clinical practice: applications and warnings

Lodi

Iannitti

Palmieri

2011

J Exp Clin Cancer Res

168

113

View full text Add to dashboard Cite

show abstract

“…TRM occurred in 4 patients (10%). The best tumor responses were: 1 complete response (CR) (2%), 7 partial response (PR) (18 %) and 10 stable disease (SD) (26%), leading to an over all disease control in 18 of 39 patients (46%) [63,64]. The exploitation of GvT effect with allo-HSCT in refractory mCRC might be an alternative to conventional strategies and may sometimesyield favorable outcomes, especially in the presence of chronic GvHD, among young patients with refractory mCRC.…”

Section: Gvt Effect In Refractory and Resistant Colorectal Cancermentioning

confidence: 99%

Graft-versus-cancereffect and innovative approaches in the treatment of refractory solid tumors

Şahin

Demirer

2020

Turk J Med Sci

View full text Add to dashboard Cite

Background/aim: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) has been used for the treatment of various refractory solid tumors during the last two decades. After the demonstration of graft-versus-leukemia (GvL) effect in a leukemic murine model following allo-HSCT from other strains of mice, graft-versus-tumor (GvT) effect in a solid tumor after allo-HSCT has also been reported in a murine model in 1984. Several trials have reported the presence of a GvT effect in patients with various refractory solid tumors, including renal, ovarian and colon cancers, as well as soft tissue sarcomas [1]. The growing data on haploidentical transplants also indicate GvT effect in some pediatric refractory solid tumors. Novel immunotherapy-based treatment modalities aim at inducing an allo-reactivity against the metastatic solid tumor via a GvT effect. Recipient derived immune effector cells (RDICs) in the antitumor reactivity following allo-HSCT have also been considered as an emerging therapy for advanced refractory solid tumors. Conclusion:This review summarizes the background, rationale, and clinical results of immune-based strategies using GvT effect for the treatment of various metastatic and refractory solid tumors, as well as innovative approaches such as haploidentical HSCT, CAR-T cell therapies and tumor infiltrating lymphocytes (TIL).

show abstract

“…In a study including six advanced mCRC patients, one complete response and one mixed response, including regression of lung and lymph-node metastasis and progression of liver metastasis were obtained[59]. In a multicenter EBMT trial, among 39 patients with progressive mCRC overall disease control was achieved in 18 (46%) and 1 complete (2%), 7 partial (18%), and 10 stable disease responses (26%) were reported after allo-HSCT[60]. Allo-HSCT with RIC might be an alternative to conventional strategies, especially in young patients with refractory mCRC.…”

Section: Gvt Effectmentioning

confidence: 99%

Review of allogeneic hematopoietic stem cell transplantation with reduced intensity conditioning in solid tumors excluding breast cancer

Karadurmuş¹,

Şahin²,

Başgöz³

et al. 2016

WJT

View full text Add to dashboard Cite

Solid tumors in adults constitute a heterogeneous group of malignancy originating from various organ systems. Solid tumors are not completely curable by chemotherapy, even though some subgroups are very chemo-sensitive. Recently, oncologists have focused on the use of allogeneic hematopoietic stem cell transplantation (allo-HSCT) with reduced intensity conditioning (RIC) for the treatment of some refractory solid tumors. After the demonstration of allogeneic graft-versus-leukemia effect in patients with hematological malignancies who received allo-HSCT, investigators evaluated this effect in patients with refractory metastatic solid tumors. According to data from experimental animal models and preliminary clinical trials, a graft-versus-tumor (GvT) effect may also be observed in the treatment of some solid tumors (e.g., renal cell cancer, colorectal cancer, etc.) after allo-HSCT with RIC. The use of RIC regimens offers an opportunity of achieving full-donor engraftment with GvT effect, as well as, a reduced transplant-related mortality. Current literature suggests that allo-HSCT with RIC might become a choice for elderly and medically fragile patients with refractory metastatic solid tumors.

show abstract

Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation in Metastatic Colorectal Cancer as a Novel Adoptive Cell Therapy Approach. The European Group for Blood and Marrow Transplantation Experience

Cited by 26 publications

References 51 publications

Stem cells in clinical practice: applications and warnings

Stem cells in clinical practice: applications and warnings

Graft-versus-cancereffect and innovative approaches in the treatment of refractory solid tumors

Review of allogeneic hematopoietic stem cell transplantation with reduced intensity conditioning in solid tumors excluding breast cancer

Contact Info

Product

Resources

About